is capable of producing lipolytic activity in response to heparin. LeQuire, Hamilton, Adams, and Merrill (16) also found increases in lipolytic activity of blood drawn from the inferior vena cava after injection of heparin into the portal vein. The relative importance in intact animals of various tissues as sources of PHLA has not been clearly established.
Studies in man have shown a decrease in the efficiency of hepatic removal of lipolytic activity in patients with cirrhosis (17) . This has been confirmed in animals subjected either to carbon tetrachloride induced necrosis or to functional hepatectomy (17) (18) (19) . Thus it would appear that the maximal levels of PHLA should be higher or the same in cirrhotic patients as compared with normal controls. However, when PHLA was determined by improved assay techniques, significantly lower levels of lipolytic activity were found in cirrhotic patients than in normal subjects (19) (20) (21) .
A possible explanation for the finding of lower levels of PHLA in cirrhotic patients lies in the hypothesis that the liver serves as an important source of PHLA in the normal individual, and this source is compromised in patients with cirrhosis. In this investigation of the effect of heparin injection on hepatic venous PHLA in intact dogs and man, we have shown that the liver can release PHLA in animals and man and that the liver may be an important source of this enzyme.
Methods
Four groups of healthy mongrel dogs were used (Table  I) . Heparin was injected into the portal vein in animals with an intact liver (protocol A) and at a comparable site after total hepatectomy (protocol B). The effect of heparin injected into the peripheral circulation was studied in animals with an intact liver (protocols C and D), and also in an animal after hepatectomy (protocol E).
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Two patients were studied during the course of clinically indicated hepatic vein catheterizations.
Patient A.B. was a 52-year-old white man, who had histologically confirmed postnecrotic cirrhosis and who appeared very fit on clinical examination. A hard liver was palpable approximately 5 cm below the xiphoid in the epigastrium. The spleen was very firm and palpable 6 cm below the left costal margin. No ascites, hepatic fetor, or asterixis was detected. Esophageal varices were revealed radiographically by barium swallow, and an extensive portosystemic collateral circulation was demonstrated by splenic venogram. The intrasplenic pressure was 25 mm Hg and the wedged hepatic vein pressure 35 mm Hg. Laboratory studies showed a hematocrit of 47, serum total bilirubin 0.7 mg per 100 ml, albumin 3.3 g per 100 ml, alkaline phosphatase 11 King-Armstrong units per 100 ml, aspartate transaminase 21 international units per L, and prothrombin time 13 seconds (control 12 seconds).
Patient R.B. was a 40-year-old white man, who had histologically confirmed postnecrotic cirrhosis. An end to side portacaval shunt, which was functioning at the time of our study, had been constructed 6 years previously. He appeared chronically ill, was jaundiced, and had a small amount of ascites. Laboratory investigations showed a hematocrit of 31, serum total bilirubin 7.7 mg per 100 ml, albumin 1.6 mg per 100 ml, alkaline phosphatase 27 King-Armstrong U per 100 ml, aspartate transaminase 47 IU per L, and prothrombin time 18 seconds (control 14 seconds).
Preparation of animals. Dogs maintained on a normal kennel diet and weighing 12 to 28 kg were fasted for 12 to 15 hours and lightly anesthetized with intravenous pentobarbital. Anesthesia was then maintained with equal volumes of nitrous oxide and oxygen through a cuffed endotracheal tube. All operations were carried out with aseptic precautions through a mid-line thoracoabdominal incision. Catheters were placed into the main left hepatic vein via the right jugular vein, into the portal vein via a distal ileal vein, and into the vena cava and abdominal aorta below the renal vessels via the right femoral vein and artery. All catheters were kept patent with a slow infusion of 0.9% (wt/vol) sodium chloride. The location of the tip of each catheter was confirmed by palpation before any blood samples were taken and further confirmed by dissection at the conclusion of the experiment. In those animals subjected to hepatectomy, a preliminary end to side portacaval shunt was constructed and the liver then totally excised.
Injection of heparin. After drawing base-line specimens, sodium heparin,' 10 U (0.1 mg) per kg body weight was injected into the designated blood vessel (Table I) . Injections into the femoral artery (protocols D and E) were made through an additional catheter that had been introduced percutaneously (22) into the vessel for a short distance in a distal direction without interfering with blood flow to the limb. During injection of heparin, the femoral artery was temporarily oc1Boots Pure Drug Company Ltd., London, England. (21) .
Assay for lipolytic activity. All estimations were done in duplicate by a method described previously using 0.2 ml of plasma (20) . The (23) . Free fatty acid release induced by postheparin plasma from the hepatic vein was determined using 5 mg each of chylomicrons and lipoproteins, in separate experiments. Final volume of assay system was 1.5 ml. FFA release after 1 hour was measured.
Clearing activity was also studied by measuring changes in optical density of coconut oil emulsion at 570 A using the method of Korn (23). 4.5 ml of postheparin plasma was incubated with 0.3 ml of 2% coconut oil emulsion for 1 hour at 37°. The effect of 1.0 M NaCl on lipolysis and clearing was also determined.
Inhibitor evaluation. The possibility that demonstration of lower PHLA in hepatectomized dogs might be due to accumulation of a plasma inhibitor normally removed by the liver was investigated. Preheparin plasma of a hepatectomized dog was mixed with postheparin plasma of a dog with intact liver, and FFA release was measured. Final volume of the assay system was kept constant using Tris buffer.
Studies in man. The patients were fasted for 12 to 14 hours and received 200 mg secobarbital 2 hours before study. A right hepatic vein was catheterized with a no. 9 Cournand catheter introduced via the basilic vein under fluoroscopic control and patency maintained by a slow infusion of 0.9% (wt/vol) sodium chloride. Arterial blood was obtained from an indwelling polyethylene catheter introduced percutaneously via the femoral artery (22) . Heparin was injected into the femoral vein in one patient (A.B.) and into the aorta above the celiac axis in the other patient (R.B.). Dosage of heparin and handling and assay of blood samples were identical with the techniques employed in the animal experiments.
The differences between means were analyzed by t test using paired comparisons when applicable (24) . The second group of animals (protocol B) underwent total surgical hepatectomy (Table  III) . Heparin was injected into the supradiaphragmatic inferior vena cava just above the level of the ligated hepatic veins. This injection site was selected to provide conditions comparable with portal vein injection in the intact animals. The mean maximal arterial levels of PHLA were significantly lower in the hepatectomized animals than in animals with intact livers (p < 0.05). Rapid release of the enzyme, as had been found in the dogs with an intact liver, was not seen in these experiments (Figure 1) .
Preheparin plasma of a hepatectomized dog failed to inhibit lipolytic activity when incubated with postheparin plasma of a dog with intact liver. Thus the lower lipolytic activity seen after hepatectomy was not due to the presence of inhibitor substances in plasma (Table IV) .
The effects of heparin injection into the peripheral arterial circulation were followed in a third group of animals (protocols C and D). In an initial experiment (Table V) liver directly by reflux via hepatic artery, heparin was injected into the left femoral artery below the groin while the artery proximal to the site of injection was momentarily occluded (Table VI) . Under these conditions of administration heparin would initially circulate through the hind limb, allowing opportunity for the release of PHLA from the limb, before reaching the liver via the hepatic artery and portal vein.
Injection of heparin into the femoral artery resulted in the release of small amounts of PHLA from the hind limb, as indicated by an initial positive difference between the mean lipolytic activity in inferior vena cava as compared with aorta (p < 0.05). During the initial 15 seconds there was no change in the lipolytic activity in hepatic vein. However, beginning 30 seconds (Table VII) . Ten minutes after injection of heparin in the hepatectomized animal, the levels of PHLA in both aorta and vena cava were below the 95 % confidence limits of the mean of the peripherally injected intact animals, indicating a significantly lower release of PHLA into the circulation in the absence of the liver. In addition, the lipolytic activity in the vena cava remained above that of the aorta throughout the first 10 minutes after heparin injection, implying that the hind limb tissues were the chief source of the small amounts of PHLA released into the circulation under these conditions.
With regard to hepatic removal of PHLA, there is a negative PHLA gradient across the tact dogs are significant throughout this period liver during the period from 20 to 45 minutes (p < 0.05).
after heparin injection in all intact animals studied Hepatic vein plasma, obtained in the first circu-(protocols A, C, and D; Tables II, V, and VI). lation after heparin injection into the portal vein, The pooled arterial-hepatic vein and portal vein-and inferior vena cava plasma, obtained in the first hepatic vein mean activity differences of the in-circulation after heparin injection into the femoral artery, were capable of effecting the optical clearing of coconut oil emulsion. This clearing was inhibited by 1.0 M sodium chloride (Table VIII) . These plasmas were also capable of hydrolyzing chylomicrons and low density lipoproteins. The chylomicron and low density lipoprotein lipolysis was also inhibited by 1.0 M sodium chloride (Table IX) .
Both of the patients studied showed increases in hepatic vein PHLA within 15 seconds after heparin injection, whereas simultaneous samples taken from the iliac artery showed little change in PHLA levels. The level of hepatic vein PHLA remained above that of arterial blood for at least 4 minutes after heparin injection (Table X) .
Discussion
In our experiments, injection of heparin into the portal vein of intact dogs resulted in release of PHLA into the hepatic vein within 5 seconds. A rise in PHLA in the aorta was not observed until at least 15 seconds after heparin injection into the portal vein and occurred at the same time as the arrival in the aorta of radioactive albumin that had been simultaneously injected with the heparin. The lipolytic activity measured in the aorta at this time represents, in our view, the arrival of the bolus of PHLA that had been released from the liver. It is probable that most of the PHLA measured in the aorta during at (13, 14) who have failed to demonstrate PHLA release from a perfused liver. In those older studies, blood samples were not obtained within the first few minutes after heparin injection. Therefore the rapid release of PHLA was not observed.
During the latter portions of the experiments on dogs with intact livers, the removal of PHLA from the circulation by the liver is apparent. There is a significant net decrease in PHLA when arterial and portal vein levels are compared with hepatic vein levels during the period from 20 to 45 minutes after heparin injection. Our observations are in accord with the findings, in both animals (13) (14) (15) and in man (17, 21) , of investigators who have collected blood samples 10 minutes or later after heparin injection and have demonstrated hepatic removal of PHLA. Available evidence indicates that the low activity observed in hepatic vein blood 10 minutes after heparin injection is not due to the presence of inhibitor substances (21, 25) .
One of the patients (A.B.) had portal hypertension with an extensive portasystemic collateral circulation. It is probable that much of the portal blood flow in this patient was shunted around the liver via collaterals. The other patient (R.B.) had had an end to side portacaval shunt. The blood supply to the liver after this operation is entirely arterial. The possibility of PHLA release from other portions of the splanchnic circulation affecting the PHLA level in hepatic vein is thus obviated. Both of the patients exhibited an increase in hepatic vein PHLA in response to injection of heparin into the systemic circulation. Hepatic vein PHLA increased relatively rapidly after heparin injection and remained above the arterial PHLA level throughout the early portion of the experiment, implying that the enzyme was being released from the liver. The pattern of response in man was similar to that in the animals.
The peak levels of PHLA seen in both patients were approximately one-tenth those found in normal controls (21 (27) . Our findings raise the question as to whether another mechanism, possibly involving prior lipolysis, may be involved in the hepatic uptake of glyceride. Summary 1) Postheparin plasma lipolytic activity was measured simultaneously in hepatic vein, abdominal aorta, portal vein, and inferior vena cava in 11 intact and five hepatectomized dogs after injection of heparin into the portal vein or a systemic artery.
2) In the animals, significant postheparin lipolytic activity was released from liver after portal vein and systemic arterial injection of heparin in intact dogs. This response was significantly impaired after hepatectomy.
3) The lipolytic activity liberated from the liver showed characteristics similar to those of lipoprotein lipase.
4) Studies of postheparin plasma lipolytic activity were also conducted in two cirrhotic patients undergoing hepatic vein catheterization. Postheparin plasma lipolytic activity was also apparently released from the liver in these patients in response to heparin injection into the systemic circulation.
5) Whether lipolytic activity liberated from the liver plays some physiological role in hepatic uptake of glycerides remains to be determined.
